Martin Caroline, Nielsen Soren U, Ibrahim Siti, Bassendine Margaret F, Toms Geoffrey L
The Liver Research Group, School of Clinical Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
J Med Virol. 2008 May;80(5):816-23. doi: 10.1002/jmv.21150.
HCV recovered from low density fractions of infected blood is associated with lipid and host apo-lipoproteins in lipo-viro-particles (LVP). It has been proposed that these particles are capable of binding and entering hepatocytes by viral glycoprotein independent mechanisms utilizing uptake pathways of normal host lipoproteins after binding to cell surface glycosaminoglycans (GAG), the low density lipoprotein receptor (LDL-r) or scavenger receptor B1 (SR-B1). In this study binding to human hepatoma cells of HCV low density RNA containing particles, semi-purified from macerates of infected human liver, is compared with that of normal host low density lipoprotein (LDL). Binding of both LDL and HCV low density RNA containing particles paralleled LDL-r but not SR-B1 expression on the recipient cells. Binding of both particle types was sensitive to suramin at 0 degrees C but less so at 37 degrees C suggesting that they both bind initially to GAG but, at 37 degrees C, are internalized or transferred to a suramin resistant receptor. Suramin resistant uptake of both particles was blocked in the presence of excess LDL or oxidized LDL. However, whilst LDL uptake was blocked by anti-apoB-100, HCV low density RNA uptake was enhanced by anti-apoB100 and further enhanced by a cocktail of anti-apo-B100 and anti-apoE. Pre-incubation of HCV low density RNA containing particles with antibodies to the E2 glycoprotein had little or no effect on uptake. These data indicate that whilst liver derived HCV RNA containing particles are taken up by HepG2 cells by a virus glycoprotein independent mechanism, the mechanism differs from that of LDL uptake.
从感染血液的低密度组分中回收的丙型肝炎病毒(HCV)与脂质病毒颗粒(LVP)中的脂质和宿主载脂蛋白相关。有人提出,这些颗粒能够通过病毒糖蛋白非依赖机制结合并进入肝细胞,该机制利用正常宿主脂蛋白在与细胞表面糖胺聚糖(GAG)、低密度脂蛋白受体(LDL-r)或清道夫受体B1(SR-B1)结合后的摄取途径。在本研究中,将从感染人肝脏匀浆中半纯化的含HCV低密度RNA颗粒与人肝癌细胞的结合情况与正常宿主低密度脂蛋白(LDL)进行了比较。LDL和含HCV低密度RNA颗粒的结合与受体细胞上的LDL-r表达平行,但与SR-B1表达无关。两种颗粒类型的结合在0℃时对苏拉明敏感,但在37℃时敏感性较低,这表明它们最初都与GAG结合,但在37℃时被内化或转移到对苏拉明耐药的受体上。在存在过量LDL或氧化LDL的情况下,两种颗粒对苏拉明耐药的摄取均被阻断。然而,虽然抗载脂蛋白B-100可阻断LDL的摄取,但抗载脂蛋白B100可增强含HCV低密度RNA的摄取,抗载脂蛋白B-100和抗载脂蛋白E的混合物可进一步增强其摄取。用针对E2糖蛋白的抗体对含HCV低密度RNA的颗粒进行预孵育对摄取几乎没有影响。这些数据表明,虽然源自肝脏的含HCV RNA颗粒通过病毒糖蛋白非依赖机制被HepG2细胞摄取,但其机制与LDL摄取不同。